Search Results

Nyxoah announced that the Company submitted the fourth and final module of its Premarket Approval application for Genio to the U.S. Food and Drug Administration (FDA).

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 in New York.

Nyxoah SA announced the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 5,374,755 of its ordinary shares at an offering price of $9.25 per share, before underwriting discounts and commissions.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close.

Nyxoah Reports First Quarter 2024 Financial and Operating Results Announced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024.

Nyxoah SA announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, in which 5,374,755 shares of its ordinary shares were sold at an offering price of $9.25 per share, before underwriting discounts and commissions.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”) today reported financial and operating results for the fourth quarter and financial year 2023.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.

Nyxoah SA announced that it has reduced the maximum amount of 6,000,000 ordinary shares available for issuance under its “at-the-market” offering by an amount of 1,569,139 ordinary shares, or share capital of EUR 269,579, resulting in a maximum of 4,430,861 ordinary shares to be issued under its “at-the-market” offering, of which 3,662,699 ordinary shares remain available for issuance, and an increase of the authorized capital that is available to the board of directors by EUR 269,579.